{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:16:26Z","timestamp":1762352186620,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ghir.2012.02.004","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T17:45:51Z","timestamp":1331919951000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy"],"prefix":"10.1016","volume":"22","author":[{"given":"Stefan M.","family":"Gehrig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hoeflich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timur","family":"Naim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon S.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2012.02.004_bb0005","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1172\/JCI30556","article-title":"Interplay of IKK\/NF-\u03baB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy","volume":"117","author":"Acharyya","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ghir.2012.02.004_bb0150","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/mus.20970","article-title":"Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice","volume":"37","author":"Bani","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ghir.2012.02.004_bb0015","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2353\/ajpath.2008.071009","article-title":"L-arginine decreases inflammation and modulates the nuclear factor-\u03baB\/matrix metalloproteinase cascade in mdx muscle fibers","volume":"172","author":"Hnia","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ghir.2012.02.004_bb0020","series-title":"Myology","first-page":"1133","article-title":"Dystrophinopathies","author":"Engel","year":"1994"},{"key":"10.1016\/j.ghir.2012.02.004_bb0025","doi-asserted-by":"crossref","first-page":"15603","DOI":"10.1073\/pnas.95.26.15603","article-title":"Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function","volume":"95","author":"Barton-Davis","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ghir.2012.02.004_bb0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.yexcr.2004.05.023","article-title":"IGF-1 induces human myotube hypertrophy by increasing cell recruitment","volume":"299","author":"Jacquemin","year":"2004","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ghir.2012.02.004_bb0035","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1210\/endo.136.11.7588220","article-title":"Effect of insulin-like growth factor I in murine muscular dystrophy","volume":"136","author":"Zdanowicz","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2012.02.004_bb0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3181\/00379727-218-44294","article-title":"Insulin-like growth factor-I and high protein diet decrease calpain-mediated proteolysis in murine muscular dystrophy","volume":"218","author":"Wingertzahn","year":"1998","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ghir.2012.02.004_bb0045","doi-asserted-by":"crossref","unstructured":"G.S. Lynch, Novel therapies for muscular dystrophy. Expert Opin. Therapeutic Patents 11 (2001) 587\u2013601.","DOI":"10.1517\/13543776.11.4.587"},{"key":"10.1016\/j.ghir.2012.02.004_bb0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1358\/dot.1998.34.1.485201","article-title":"The preclinical rationale for the use of insulin-like growth factor-I in amyotrophic lateral sclerosis","volume":"34","author":"Festoff","year":"1998","journal-title":"Drugs Today"},{"key":"10.1016\/j.ghir.2012.02.004_bb0055","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X-chromosome linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ghir.2012.02.004_bb0060","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.ghir.2012.02.004_bb0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0960-8966(99)00126-1","article-title":"Pre-clinical screening of drugs using the mdx mouse","volume":"10","author":"Granchelli","year":"2000","journal-title":"Neuromusc. Dis."},{"key":"10.1016\/j.ghir.2012.02.004_bb0070","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/S0002-9440(10)64502-6","article-title":"Improved contractile function of the mdx dystrophic mouse diaphragm muscle following IGF-I administration","volume":"161","author":"Gregorevic","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ghir.2012.02.004_bb0075","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/mus.20082","article-title":"Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice","volume":"30","author":"Gregorevic","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ghir.2012.02.004_bb0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0092-8674(00)80532-2","article-title":"Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy","volume":"90","author":"Deconinck","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ghir.2012.02.004_bb0085","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1074\/jbc.M110.172189","article-title":"Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I","volume":"286","author":"Metzger","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ghir.2012.02.004_bb0090","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ghir.2011.07.006","article-title":"PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders","volume":"21","author":"Saenger","year":"2011","journal-title":"Growth Horm. IGF Res."},{"key":"10.1016\/j.ghir.2012.02.004_bb0095","unstructured":"S. Saenger, B. Holtmann, M.R. Nilges, et al., in press Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity. Amyotroph. Lateral Scler."},{"key":"10.1016\/j.ghir.2012.02.004_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.expneurol.2011.09.015","article-title":"Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease","volume":"232","author":"Jablonka","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ghir.2012.02.004_bb0105","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1210\/endo.140.12.7169","article-title":"Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain","volume":"140","author":"Hoeflich","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2012.02.004_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2353\/ajpath.2010.090760","article-title":"Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology","volume":"176","author":"Gehrig","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ghir.2012.02.004_bb0115","doi-asserted-by":"crossref","first-page":"E499","DOI":"10.1152\/ajpendo.00101.2006","article-title":"Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice","volume":"291","author":"Schertzer","year":"2006","journal-title":"Am. J. Physiol. Endo. Metab."},{"key":"10.1016\/j.ghir.2012.02.004_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/84839","article-title":"Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle","volume":"27","author":"Musaro","year":"2001","journal-title":"Nature Genet."},{"key":"10.1016\/j.ghir.2012.02.004_bb0125","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/sj.gt.3302817","article-title":"Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration and functional repair after injury","volume":"13","author":"Schertzer","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ghir.2012.02.004_bb0130","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1242\/jcs.061119","article-title":"A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo","volume":"123","author":"Shavlakadze","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ghir.2012.02.004_bb0135","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.49.6.1621","article-title":"Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS\/IGF-I Study Group","volume":"49","author":"Lai","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ghir.2012.02.004_bb0140","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1212\/WNL.51.2.583","article-title":"A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS\/IGF-I Study Group","volume":"51","author":"Borasio","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ghir.2012.02.004_bb0145","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1212\/01.wnl.0000335970.78664.36","article-title":"Subcutaneous IGF-1 is not beneficial in 2-year ALS trial","volume":"71","author":"Sorenson","year":"2008","journal-title":"Neurology"}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637412000196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637412000196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:47:11Z","timestamp":1761086831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637412000196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1096637412000196"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2012.02.004","relation":{},"ISSN":["1096-6374"],"issn-type":[{"type":"print","value":"1096-6374"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2012.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}